SHERWOOD, OR, United States, via ETELIGIS INC., 11/14/2014 – – Entia Biosciences Inc. (OTCQB: ERGO), an emerging leader in the field of nutrigenomics, announces that Marvin S. Hausman MD, CEO, will speak on the subject – “Treatment of Anemia with a Natural Mushroom-Based Medical Food ErgoD2.” The 17th International Conference of FFC, Discovery, Utilization, and Control of Bioactive Components and Functional Foods, November 18-19, 2014, will be held at the University of San Diego, San Diego, California, USA.
Entia’s ErgoD2® technology aims to treat anemia by stabilizing iron levels, reducing inflammation, and boosting the internal antioxidant system. At the core of this technology are L-Ergothioneine and Ergocalciferol, which, in clinical studies conducted by Entia in diabetes and chronic kidney disease, have been shown to stimulate iron export from the cell.
Dr. Hausman will also be Chairman of the session: “Legislation on Health Claims: Healthy, Functional and Medical foods.”
Dr. Robert B. Beelman, Ph.D., member of Entia’s Scientific Advisory Board will also be Chairman and speak at the session “Discovery of Bioactive Components.” Dr. Beelman’s talk is titled: “Serum Advanced Glycation End Products Are Reduced in Pre-Diabetics, Following a Four Month White Button Mushroom Feeding Trial.”
ErgoD2® is a proprietary pharmaceutical grade organic compound from whole food that contains the micro-nutrients L-Ergothioneine, an amino acid with a dedicated transporter (SLC22A4), and Ergocalciferol (vitamin D2). These nutrients are naturally enhanced and concentrated to therapeutic levels using Entia’s patented technology.
About Entia Biosciences, Inc.:
Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture. www.entiabio.com.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2013 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Chief Operating Officer
Entia Biosciences Inc.
13565 SW Tualatin-Sherwood Rd.
Sherwood, OR 97140
SOURCE: Entia BioSciences, Inc.